Novo Nordisk raises 2026 outlook as Wegovy pill sales reach 5.4 billion kroner

Wegovy口服藥營收達54億丹麥克朗,諾和諾德上調2026年展望

更新於: 2026年11月5日 上午01:18

Novo Nordisk raised its 2026 outlook on November 4 after stronger sales of its obesity treatments. The Danish drugmaker now expects adjusted sales and adjusted operating profit each to change by between minus 2 and plus 2 percent at constant exchange rates over the full year.

諾和諾德於11月4日上調2026年展望,主因是肥胖症治療藥物銷售較強。這家丹麥藥廠目前預期,排除匯率變動後,全年調整後營收及調整後營業利益的變化幅度,均介於負2%至正2%。

nounoutlook

Third-quarter sales reached 79.195 billion Danish kroner, up 4 percent at constant exchange rates. The company said demand for GLP-1 products increased across both its US and international businesses, particularly in obesity care.

第三季營收達791.95億丹麥克朗,按固定匯率成長4%。公司表示,美國與國際業務的GLP-1產品需求都增加,尤其是肥胖症照護相關產品。

adverbparticularly

The Wegovy pill generated 5.394 billion kroner during the quarter. By the end of September it had launched in the United States, United Arab Emirates, Britain and Germany. Four more launches subsequently brought the number of markets to eight.

Wegovy口服藥在這一季創造53.94億克朗營收。截至9月底,已在美國、阿拉伯聯合大公國、英國及德國上市;之後再增加四國,使上市市場總數達八個。

adverbsubsequently

Adjusted operating profit rose 27 percent to 31.720 billion kroner at constant exchange rates. The comparison benefited from 9 billion kroner of transformation costs recorded a year earlier, which had lowered the previous year’s base.

按固定匯率計算,調整後營業利益成長27%至317.20億克朗。比較基期受到一年前90億克朗轉型成本影響;這筆支出壓低了去年的基準數字。

verbbenefit

Reported operating profit moved in the opposite direction, falling 9 percent on the same exchange-rate basis. It included 8.7 billion kroner in non-cash impairment charges related to a drug project and changes to the manufacturing network.

財報列報的營業利益則反向變動,在相同匯率基礎下下降9%。其中包括87億克朗非現金減損費用,與一項藥物計畫及製造網絡調整有關。

nounimpairment

Chief executive Mike Doustdar said the company was preparing for a US launch of CagriSema in early 2027, subject to regulatory approval. Broader access to medicines and continued international launches remain part of its plans.

執行長Mike Doustdar表示,公司正準備於2027年初在美國推出CagriSema,但仍須監管機關核准。擴大藥物可近性及持續在國際市場上市,仍是公司計畫的一部分。

phrasesubject to
🎉

文章閱讀結束

你閱讀了 6 句重點內容。

挑戰模式

閱讀理解

What is the new adjusted annual growth range?

✓

正確答案

Minus 2 to plus 2 percent

How much did quarterly sales grow at constant exchange rates?

✓

正確答案

4 percent

How many markets had the Wegovy pill reached after later launches?

✓

正確答案

Eight

Why was the adjusted profit comparison helped?

✓

正確答案

The prior year included large transformation costs

When is the US CagriSema launch planned, subject to approval?

✓

正確答案

Early 2027

Ringoo Icon

使用 Ringoo App 學習更快速

追蹤你的學習進度,並透過互動式練習獲得即時回饋。